Melanoma

- Uveal Melanoma
  - IRB#16162: A Phase 1, Open-label, Study Evaluating Single and Repeated Escalating Intravitreal Doses of ICON-1 in Patients with Uveal Melanoma Who are planned to Undergo Enucleation

- Adjuvant Therapies
  - Stages 2B, 2C, or 3 resectable
    - IRB#11848: A Phase III Placebo-controlled trial of POL-103A Vaccine in Post-resection Melanoma Patients with High Risk of Recurrence
  - Stages 3 or 4 resectable
    - IRB#15661: A Phase III Randomized Trial Comparing Either High Dose Interferon or Ipilimumab to Pembrolizumab in Patients with High Risk Resected Melanoma
  - Non-Mutation Specific
    - New study coming soon

- Stages 3 or 4, unresectable
  - IRB#11313: A Phase II Study of Ipilimumab and HF10 for Stage IIIIB/C, or IV Unresected or Metastatic Malignant Melanoma

- Mutation Specific
  - BRAF V600 Mutation
  - NRAS Mutation
  - C-Kit Mutation
    - IRB#15298: Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With BRAFV600 Mutant Melanoma

Please refer to Phase I studies for more clinical trial opportunities

Key
- Open for Enrollment
- In Development
- Enrollment on Hold

10/24/16
www.ohsu.edu/cancer